Trial Profile

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Biomarker; Pharmacodynamics; Pharmacogenomic
Acronyms COMET
Sponsors UNICANCER

25 Jan 2023 Status changed from active, no longer recruiting to completed.
14 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
14 Mar 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com